MP24-05 LONG-TERM FOLLOW-UP AND PROGNOSTIC FACTOR ANALYSIS IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO RECEIVE PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED LUTETIUM-177 (177LU)

You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) II (MP24)1 Sep 2021MP24-05 LONG-TERM FOLLOW-UP AND PROGNOSTIC FACTOR ANALYSIS IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO RECEIVE PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED LUTETIUM-177 (177LU) Michael Sun, Charlene Thomas, Benedict Ho, Junaid Niaz, Jones Nauseef, Joseph Osborne, Ana Molina, Cora Sternberg, David Nanus, Neil Bander, and Scott Tagawa SunMichael Sun More articles by this author , ThomasCharlene Thomas HoBenedict Ho NiazJunaid Niaz NauseefJones Nauseef OsborneJoseph Osborne MolinaAna Molina SternbergCora Sternberg NanusDavid Nanus BanderNeil Bander TagawaScott View All Author Informationhttps://doi.org/10.1097/JU.0000000000002015.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION OBJECTIVE: 177Lu-PSMA is a promising investigational treatment for men with mCRPC. Optimal selection biomarkers remain be defined. Here, we report combined analysis mCRPC treated on sequential prospective clinical trials PSMA-targeted 177Lu. METHODS: Patients from 2003 through 2020, completion at least one year prior analysis, were included. Variables included type PSMA-targeting, dose level, co-morbidities, CALGB (Halabi) prognostic risk group, PSMA imaging, circulating tumor cell (CTC) counts, known DNA-repair (DDR) alterations (germline and/or somatic), receipt FDA-approved subsequent therapies. As previously published, imaging was scored based upon maximum uptake relative mean liver uptake. RESULTS: 76 (59.9%) receiving 177Lu-J591, 51 (40.1%) 177Lu-PSMA-617 in analysis. Total median OS 20.7 months (95% CI 17.4-24.0); 177Lu-J591 mOS 23.3 mo [95% 21.1-32.6], 16.7 10.9-20.7]. 26 (20.5%) alive 3 years after treatment. Factors associated longer score (28.1 vs. 16.9, p <0.0001), CTC decline (24.9 19.2, p=0.046), therapy 14.8, p=0.0002). Overall, those stronger lived shorter, though when restricted PET 177Lu-PSMA-617, higher SUV (18 10 mo, p=0.015). Higher administered activity (22.1 18.6, p=0.074) DDR mutations (33.9 20.6, p=0.24) tended OS. On multivariable high Halabi group (HR 1.78, 95% 1.16-2.73, p=0.009) total number therapies 0.79, 0.71-0.89, <0.001) retained their significance, trend 0.68, 0.34-1.36, p=0.30). CONCLUSIONS: For patients 177Lu, may influence mutations, activity, count Heterogeneity modalities dataset limit implications. Source Funding: NIH, Department Defense, Weill Cornell Medicine, Prostate Cancer Foundation © 2021 American Urological Association Education Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e413-e413 Advertisement Copyright & Permissions© Inc.MetricsAuthor Information Expand Loading ...